Evidence map›Paper›PMID 23322984›Full record

ReviewWorld journal of gastroenterology2012

Present and future cell therapies for pancreatic beta cell replenishment.

Juan Domínguez-Bendala, Camillo Ricordi

Abstract readReview
In one paragraph

Review in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Cell therapies for pancreatic beta-cell replenishment.Italian journal of pediatrics · 2016
    Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Juan Domínguez-BendalaDiabetes Research Institute, University of Miami Leonard M. Miller School of Medicine, Miami, FL 33136, USA. jdominguez2@med.miami.edu
Camillo Ricordi

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

If only at a small scale, islet transplantation has successfully addressed what ought to be the primary endpoint of any cell therapy: the functional replenishment of damaged tissue in patients. After years of less-than-optimal approaches to immunosuppression, recent advances consistently yield long-term graft survival rates comparable to those of whole pancreas transplantation. Limited organ availability is the main hurdle that stands in the way of the widespread clinical utilization of this pioneering intervention. Progress in stem cell research over the past decade, coupled with our decades-long experience with islet transplantation, is shaping the future of cell therapies for the treatment of diabetes. Here we review the most promising avenues of research aimed at generating an inexhaustible supply of insulin-producing cells for islet regeneration, including the differentiation of pluripotent and multipotent stem cells of embryonic and adult origin along the beta cell lineage and the direct reprogramming of non-endocrine tissues into insulin-producing cells.

Indexed as

AnimalsCell DifferentiationCell LineageDiabetes MellitusEmbryonic Stem CellsHumansInsulinInsulin-Secreting CellsIslets of Langerhans TransplantationMesenchymal Stem CellsMiceRegenerationStem Cell TransplantationTissue EngineeringInsulinBeta cell differentiationHuman embryonic stem cellsInduced pluripotent stem cellsIslet transplantationMesenchymal stem cellsReprogramming

Identifiers

PMID23322984
PMCPMC3531670

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.